Cencora (COR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended June 2025, Cencora (COR) reported revenue of $80.66 billion, up 8.7% over the same period last year. EPS came in at $4.00, compared to $3.34 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $80.33 billion, representing a surprise of +0.41%. The company delivered an EPS surprise of +5.82%, with the consensus EPS estimate being $3.78.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Cencora performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Revenue- Total U.S. Healthcare Solutions: $72.88 billion compared to the $72.81 billion average estimate based on four analysts. The reported number represents a change of +8.5% year over year.Revenue- Total International Healthcare Solutions: $7.79 billion versus the four-analyst average estimate of $7.3 billion. The reported number represents a year-over-year change of +10.5%.Revenue- Intersegment eliminations: $-3.47 million versus $-3.89 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +63.6% change.View all Key Company Metrics for Cencora here>>>Shares of Cencora have returned -1.9% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Zacks' Research Chief Picks Stock Most Likely to "At Least Double"Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cencora, Inc. (COR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks